Monoclonal antibodies (MoAbs) have been used
since the 1980s to treat both solid tumors and hematologic
neoplasms. Lymphoma was a ripe area for early MoAb trials, since
extensive research on the normal immune system led to the
characterization of many lymphocyte surface antigens that could serve
as potential therapeutic targets. These early trials yielded few
responses, but many insights, including the following:
Some (but not all) surface proteins can be depleted from the cell
surface by being shed into the serum, internalized into the cell, or modulated.
Murine antibodies have a short half-life in humans.
Human effector functions would be more effectively mediated by a
human Fc portion of the antibody than by a murine Fc fragment.
Immunogenicity is a limitation of murine antibodies.
Even in these early trials, it was observed that MoAb therapy could
be effective, and that it was both feasible and relatively nontoxic.
The most common toxicity, which was noted to some extent in virtually
all of the trials, was a symptom complex, probably cytokine-mediated,
of fever, chills, sweats, and, occasionally, bronchospasm and
hypotension.[1,3,4] However, even with murine antibodies, severe
allergic or hypersensitivity reactions were quite infrequent, as were
late effects, such as serum sickness.
The CD20 molecule is an appealing target for a therapeutic MoAb.[5-7]
It is expressed on B-cells from the pre-B-cell stage to the activated
B-cell stage but is not expressed on stem cells, normal plasma cells,
or cells of other lineages. In addition, CD20 is expressed on most
B-cell lymphomas and chronic lymphocytic leukemia cells and on 50% of
pre-B-cell acute lymphoblastic leukemias.[2,6,8] It is not shed,
internalized, or modulated. Evidence indicates that CD20 may play a
role in cell-cycle entry and progression in B-lymphocytes,[9-11]
suggesting that anti-CD20 MoAb therapy may have B-cell growth
regulatory effects that are independent of human effector functions.
The chimeric human/mouse anti-CD20 antibody rituximab (IDEC-C2B8
[Rituxan]) was developed to minimize some of the drawbacks of murine
antibodies. A chimeric antibody is expected to be less immunogenic
than a murine MoAb, and to have a longer half-life. A chimeric MoAb
should be more effective in terms of mediating human effector
functions, such as complement- mediated cell lysis and
antibody-dependent cell-mediated cytotoxicity. Also, accumulating
evidence suggests that rituximab may induce apoptosis, as well as
sensitize resistant human cell lines to the effects of chemotherapy.
This theoretical background provided the basis for the development of
rituximab. It also underlies the clinical success of this antibody,
which led to its being the first MoAb to gain FDA approval for the
treatment of a malignancy. In a real sense, rituximab represents the
beginning of a promising new era in cancer therapy.
Direct and competitive binding assays were used to compare rituximab
to the murine 2B8 antibody from which it was derived; these assays
showed rituximab to have comparable affinity and specificity for the
CD20-positive SB cell line. Flow cytometry experiments showed that
normal peripheral blood B-cells bind to rituximab, whereas other
lymphocyte subsets do not.
The tissue reactivity of rituximab was tested on a panel of 32
different human tissues. Only a subset of lymphoid tissues reacted,
including those in the white pulp of the spleen, in lymphoid
follicles of the tonsil, in some lymph node B-cells, and in lymphoid
cells present in such organs as the intestine. Rituximab showed no
reactivity with epithelial cells, fibroblasts, endothelial cells, or
neuroectodermal cells, including cells of the brain and spinal cord.
The ability of rituximab to fix complement was demonstrated by
showing the binding of fluorescent C1q to cells from the SB cell line
that had been incubated with rituximab. Complement-dependent
cytotoxicity of ri-tuximab was characterized by using
chromium-51labeled SB cells that were exposed to antibody and
human serum as a source of complement. Control studies were performed
with the CD20-negative HSB cell line. Approximately 50% of the SB
target cells were lysed in the presence of rituximab, but the
CD20-negative HSB cells were not. Thus, the lysis mediated by
rituximab was antigen-specific.
Another study assessed the ability of rituximab to bind to human Fc
receptors, which are found on effector cells, including monocytes,
macrophages, and natural killer cells. Rituximab was found to bind to
both the high-affinity Fc-gamma-RI receptor and the low-affinity
Fc-gamma-RII and Fc-gamma-RIII receptors. The binding of rituximab to
Fc-gamma-RI was equivalent to that of human immunoglobulin G1 (IgG1),
and its binding to Fc-gamma-RII was stronger than that of IgG1. Thus,
not surprisingly, rituximab was found to mediate antibody-dependent
cell-mediated cytotoxicity; in the presence of rituximab, Fc
receptorpositive effector cells killed ~50% of target cells
that had adherent antigen-specific antibody.
Cell line experiments showed that rituximab can inhibit growth of
B-cell lines, including FL-18, Ramos, Raji, and DHL-4 cell lines.
Comparable growth inhibition was observed with IDEC-2B8, the murine
anti-CD20 antibody from which the variable regions of rituximab are
derived; this indicates that the human Fc region is not essential for
the growth inhibition. Of five anti-CD20 antibodies tested,
rituximab, IDEC-2B8 (IDEC Pharmaceuticals), and anti-B1 (Coulter)
inhibited cell growth more strongly than 1F5 or 2H7, and also
produced greater cell growth inhibition than did anti-CD19 or
anti-HLA-DR (human leukocyte antigenD-related) antibodies.
In studies of one of the cell lines (DHL-4), there was evidence that
anti-CD20 MoAbs induce apoptosis. Rituximab can also sensitize
resistant cell lines to the cytotoxicity of diphtheria toxin, ricin,
cisplatin (Platinol), doxorubicin, and etoposide.
In primate studies, rituximab was found to be nontoxic in cynomolgus
monkeys, and to deplete B-cells effectively from peripheral blood,
lymph nodes, bone marrow, and the spleen. In dose-ranging studies in
monkeys, doses of up to 100 mg/kg (equivalent to 1,200 mg/m² in
humans) were associated with only minor toxicity, including some
vomiting and transient decreases in platelets and white blood cells.
Preclinical studies showed that rituximab has a relatively long serum
half-life in cynomolgus monkeys. Anti-body was detectable up to 7
days after a single 10-mg/kg dose, and higher and more sustained
serum levels were noted after higher doses (30 to 100 mg/kg).
In single- and multiple-dose phase I trials, Maloney et al observed
detectable antibody for up to 10 days after a single dose of
rituximab. Higher and more sustained serum levels were seen after
multiple doses (Table 1).[13-15]
The pivotal clinical trial leading to the approval of rituximab used
a dose of 375 mg/m² weekly for 4 weeks. This trial showed a
pattern similar to the multiple-dose phase I trial: a half-life of
59.8 hours after the first dose and 174 hours after the fourth
dose.[16,17] Detectable serum rituximab levels were still present in
patients for up to 3 to 6 months after the fourth dose. Despite a
typically lower density of CD20 on small lymphocytic lymphoma (SL)
cells than on follicular lymphoma cells, patients with small
lymphocytic lymphoma had more rapid depletion of rituximab than did
patients with follicular lymphoma.
Ongoing studies are testing rituximab in a weekly × 8 schedule,
including one trial that is using an escalated dose (500 mg/m²)
for weeks 2 through 8.[19,20] Pharmacokinetic studies in these trials
will address whether stepwise higher peak rituximab levels can be
attained with repeat doses on the weekly × 8 schedule, and to
what extent antibody levels can be prolonged further.
The phase I experience with rituximab did not define any
dose-limiting toxicities (see Side Effects below).
However, since tumor regressions were seen in the phase I trials, and
the multiple-dose schedule achieved sus-tained antibody levels, the 375-mg/m²weekly
× 4 schedule was pursued, and is the schedule approved by the FDA.
1. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol
2. Anderson K, Bates M, Slaughenhoup B, et al: Expression of human B
cell-associated antigens on leukemias and lymphomas: A model of human
B cell differentiation. Blood 63:1424-1433, 1984.
3. Grossbard M, Press O, Appelbaum F, et al: Monoclonal
antibody-based therapies of leukemia and lymphoma. Blood 80:863-878, 1992.
4. Press O, Appelbaum F, Ledbetter J, et al: Monoclonal antibody 1F5
(anti-CD20) serotherapy of human B-cell lymphomas. Blood 69:584-591, 1987.
5. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in
vivo by a chimeric mouse human monoclonal antibody to CD20. Blood
6. Stashenko P, Nadler LM, Hardy R, et al: Characterization of a
human B- lymphocyte-specific antigen. J Immunol 125:1678-1685,1980.
7. Einfeld D, Brown J, Valentine M, et al: Molecular cloning of the
human B-cell CD20 receptor predicts a hydrophobic protein with
multiple transmembrane domains. EMBO J 7:711-717, 1988.
8. Zhou L-J, Tedder TF: CD20 workshop panel report, in Schlossman SF,
Boumsell L, Gilks W, et al (eds): Leucocyte Typing V. White Cell
Differentiation Antigens, pp 511-514. Oxford, Oxford University
9. Tedder T, Boyd A, Freedman A, et al: The B-cell surface molecule
B1 is functionally linked with B cell activation and differentiation.
J Immunol 135:973-979, 1985.
10. Golay JT, Clark EA, Beverley PC: The CD20 (Bp35) antigen is
involved in activation of B cells from the G0 to the G1 phase of the
cell cycle. J Immunol 135: 3795-3801, 1985.
11. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of
monoclonal anti-CD20 antibody therapy includes direct
anti-proliferative activity and induction of apoptosis in CD20
positive non-Hodgkins lymphoma cell lines (abstract). Blood
88(suppl 1): 637a, 1996.
12. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8)
monoclonal antibody sensitizes a B cell lymphoma cell line to cell
killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997.
13. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical
trial using escalating single-dose infusion of chimeric anti-CD20
monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell
lymphoma. Blood 84: 2457-2466, 1994.
14. Maloney DG, Grillo-López AJ, Bodkin DJ, et al: IDEC-C2B8:
Results of a phase I multiple-dose trial in patients with relapsed
non-Hodgkins lymphoma. J Clin Oncol 15: 3266-3274, 1997.
15. Maloney DG, Grillo-López AJ, White CA, et al: IDEC-C2B8
(Rituximab) anti-CD20 monoclonal antibody therapy in patients with
relapsed low-grade non-Hodgkins lymphoma. Blood 90:2188-2195, 1997.
16. McLaughlin P, Cabanillas F, Grillo-López AJ et al:
Pharmacokinetics and pharmacodynamics of the anti-CD20 antibody
IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma
(abstract). Blood 88(suppl 1):90a, 1996.
17. McLaughlin P, Cabanillas F, Grillo-López, AJ, et al:
IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal
trial in patients with relapsed low-grade or follicular lymphoma
(abstract). Blood 88(suppl 1):90a, 1996.
18. Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of
CD20 antigen as a characteristic marker for chronic lymphocytic
leukemia. Am J Hematol 40:259-63, 1992.
19. Piro L, White CA, Grillo-López AJ, et al: Rituxan
(rituximab, IDEC-C2B8): Interim analysis of a phase II study of once
weekly times eight dosing in patients with relapsed low-grade or
follicular non-Hodgkins lymphoma (abstract). Blood 90(suppl
20. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20
monoclonal antibody) for the treatment of patients with relapsing or
refractory aggressive lymphoma: A multicenter phase II study. Blood
21. Czuczman MS, Grillo-López AJ, Saleh M, et al:
IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade
lymphoma: Interim clinical and bcl-2 (PCR) results (abstract). Ann
Oncol 7(suppl 1):56, 1996.
22. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab
chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent
lymphoma: Half of patients respond to a 4-dose treatment program. J
Clin Oncol 16:2825-2833, 1998.
23. Horning S, Cheson B, Peterson B, et al: Response criteria and
quality assurance of responses in the evaluation of new therapies for
patients with low-grade lymphoma (abstract). Proc Am Soc Clin Oncol
24. Dillman RO: The human antimouse response. Antibody Immunocon
Radiopharm 3:1-15, 1990.
25. Ezdinli EZ, Anderson JR, Melvin F, et al: Moderate vs aggressive
chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J
Clin Oncol 3: 769-775, 1985.
26. Portlock CS, Fischer DS, Cadman E, et al: High-dose pulse
chlorambucil in advanced, low-grade non-Hodgkins lymphoma.
Cancer Treat Rep 71: 1029-1031, 1987.
27. McLaughlin P, Robertson LE, Keating JM: Fludarabine phosphate in
lymphoma: An important new therapeutic agent, in Cabanillas F,
Rodriguez MA (eds): Advances in Lymphoma Research, pp 3-14. Boston,
Kluwer Academic Publishers, 1996.
28. Pott-Hoeck C, Hiddemann W: Purine analogs in the treatment of
low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol
29. Piro LD: Cladribine in the treatment of low-grade
non-Hodgkins lymphoma. Semin Hematol 33(suppl 1):34-39, 1996.
30. Kalter S, Holmes L, Cabanillas F: Long-term results of treatment
of patients with follicular lymphomas. Hematol Oncol 5:127-138, 1987.
31. Anderson KC, Skarin AT, Rosenthal DS, et al: Combination
chemotherapy for advanced non-Hodgkins lymphomas other than
diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep
32. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine,
mitoxantrone, and dexa-methasone: An effective new regimen for
indolent lymphoma. J Clin Oncol 14:1262-1268, 1996.
33. McLaughlin P, Hagemeister FB, Swan F, et al: Intensive
conventional-dose chemotherapy for stage IV low-grade lymphoma: High
remission rates and reversion to negative of peripheral blood bcl-2
rearrangement. Ann Oncol 5(suppl 2): S73-S77, 1994.
34. Horning SJ: High-dose therapy and transplantation for low-grade
lymphoma. Hematol Oncol Clin N Am 11:919-935, 1997.
35. Davis T, Levy R, White CA, et al: Retreatments with Rituxan
(rituximab, IDEC-C2B8) have significant efficacy, do not cause HAMA,
and are a viable minimally toxic alternative in relapsed or
refractory non-Hodgkins lymphoma (abstract). Blood 90(suppl
36. Davis T, Maloney D, White CA, et al: Combination immunotherapy of
low grade or follicular non-Hodgkins lymphoma with rituximab
and alpha-interferon: Interim analysis (abstract). Proc Am Soc Clin
Oncol 17:11a, 1998.
37. Link BK, Grossbard ML, Fisher RI, et: Phase II pilot study of the
safety and efficacy of rituximab in combination with CHOP
chemotherapy in patients with previously untreated intermediate- or
high-grade NHL. Proc Am Soc Clin Oncol 17:3a. 1998.